AT 0701

Drug Profile

AT 0701

Alternative Names: Anti influenza monoclonal antibody - AIMM; AT0701

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AIMM Therapeutics
  • Developer AIMM Therapeutics; Undisclosed
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 26 Apr 2017 Phase-II clinical trials in Influenza virus infections in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
  • 14 Jan 2014 Anti-influenza monoclonal antibody - AIMM Therapeutics is available for licensing as of 14 Jan 2014.
  • 31 Dec 2013 Phase-I clinical trials in Influenza virus infections in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top